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Abstract. Background: Peginterferon–ribavirin therapy is the
current standard of care for chronic infection with hepatitis C virus
(HCV). The rate of sustained virologic response has been below 50%
in cases of HCV genotype 1 infection. Boceprevir, a potent oral
HCV-protease inhibitor, has been evaluated as an additional treat-
ment in phase 1 and phase 2 studies.
Methods:We conducted a double-blind study in which previouslyun-
treated adults with HCV genotype 1 infectionwere randomly assigned
to one of the three groups. In all the three groups, peginterferon alfa-2b
and ribavirinwere administered for 4 weeks (the lead-in period). Sub-
sequently, group 1 (the control group) received placebo plus peginter-
feron–ribavirin for 44 weeks; group 2 received boceprevir plus
peginterferon–ribavirin for 24 weeks, and those with a detectable
HCVRNA level betweenweeks8 and24 receivedplaceboplus peginter-
feron–ribavirin for anadditional 20 weeks; and group3 receivedboce-
previr plus peginterferon–ribavirin for 44 weeks. Nonblack patients
and black patients were enrolled and analyzed separately.
Results: A total of 938 nonblack and 159 black patients were treated.
In the nonblack cohort, a sustained virologic response was achieved
in 125 of the 311 patients (40%) in group 1, in 211 of the 316 patients
(67%) in group 2 (p < 0.001), and in 213 of the 311 patients (68%) in
group 3 (p < 0.001). In the black cohort, a sustained virologic
response was achieved in 12 of the 52 patients (23%) in group 1, in
22 of the 52 patients (42%) in group 2 (p = 0.04), and in 29 of the
55 patients (53%) in group 3 (p = 0.004). In group 2, a total of 44%
of patients received peginterferon–ribavirin for 28 weeks. AnemiaJournal of Hepatology 20
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Conclusions: The addition of boceprevir to standard therapy with
peginterferon–ribavirin, as compared to standard therapy alone, sig-
niﬁcantly increased the rates of sustained virologic response in pre-
viously untreated adults with chronic HCV genotype 1 infection. The
rates were similar with 24 weeks and 44 weeks of boceprevir.
(Funded by Schering-Plough [now Merck]; SPRINT-2 ClinicalTri-
als.gov number, NCT00705432)
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Abstract. Background: In patients with chronic infection with hep-
atitis C virus (HCV) genotype 1 who do not have a sustained response
to therapy with peginterferon–ribavirin, outcomes after retreatment
are suboptimal. Boceprevir, a protease inhibitor that binds to the
HCV nonstructural 3 (NS3) active site, has been suggested as an addi-
tional treatment.
Methods: To assess the effect of the combination of boceprevir and
peginterferon–ribavirin for retreatment of patients with chronic
HCV genotype 1 infection, we randomly assigned patients (in a
1:2:2 ratio) to one of the three groups. In all the three groups, pegin-
terferon alfa-2b and ribavirin were administered for 4 weeks (the
lead-in period). Subsequently, group 1 (control group) received pla-
cebo plus peginterferon–ribavirin for 44 weeks; group 2 received
boceprevir plus peginterferon–ribavirin for 32 weeks, and patients
with a detectable HCV RNA level at week 8 received placebo plus
peginterferon–ribavirin for an additional 12 weeks; and group 3
received boceprevir plus peginterferon–ribavirin for 44 weeks.
Results: A total of 403 patients were treated. The rate of sustained
virologic response was signiﬁcantly higher in the two boceprevir
groups (group 2, 59%; group 3, 66%) than in the control group
(21%, p < 0.001). Among patients with an undetectable HCV RNA
level at week 8, the rate of sustained virologic response was 86% after
32 weeks of triple therapy and 88% after 44 weeks of triple therapy.
Among the 102 patients with a decrease in the HCV RNA level of less11 vol. 55 j 1154–1158
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than 1 log(10) IU per milliliter at treatment week 4, the rates of
sustained virologic response were 0%, 33%, and 34% in groups 1, 2,
and 3, respectively. Anemia was signiﬁcantly more common in the
boceprevir groups than in the control group, and erythropoietin
was administered in 41–46% of boceprevir-treated patients and
21% of controls.
Conclusions: The addition of boceprevir to peginterferon–ribavirin
resulted in signiﬁcantly higher rates of sustained virologic response
in previously treated patients with chronic HCV genotype 1 infection,
as compared to peginterferon–ribavirin alone. (Funded by Schering-
Plough [now Merck]; HCV RESPOND-2 ClinicalTrials.gov number,
NCT00708500).B
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Fig. 1. Sprint-2 study. (A) Design. Sprint-2 is a phase 3 international double-
blind randomized study including genotype 1 naïve patients (938 non-black and
159 black) and compared a 4-weeks lead-in treatment period with PEG-IFN alfa-
2b/ribavirin, followed by (1) PEG-IFN alfa-2b/ribavirin plus placebo for 44 weeks; 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
New direct acting antivirals (DAA), such as protease and poly-
merase inhibitors, are under development for the treatment of
chronic hepatitis C [1]. Boceprevir is a linear peptidomimetic
ketoamide serine protease inhibitor that binds reversibly to the
HCV nonstructural 3 (NS3) active site. In genotype 1 patients,
very promising results have recently been reported when the
protease inhibitor boceprevir is added to the standard of care
(SOC) (PEG-IFN plus ribavirin) [2–3]. Indeed, in genotype 1 naïve
patients treatment with boceprevir plus SOC increases sustained
virological response (SVR) rates from near 40% (SOC) to approxi-
mately 70%. In genotype 1 experienced patients SVR reaches 75%
in previous relapsers and increases from 40% to 52% in previous
non responders. Therefore the standard of care for genotype 1
patients is a triple therapy with a protease inhibitor in addition
to PEG-IFN plus ribavirin.(2) response-guided therapy: boceprevir plus PEG-IFN alfa-2b/ribavirin for
24 weeks, with an additional 20 weeks of PEG-IFN alfa-2b/ribavirin only if
detectable HCV RNA during weeks 8–24; or (3) boceprevir plus PEG-IFN alfa-2b/
RBV for 44 weeks) [2]. (B) Results. Boceprevir plus PEG-IFN alfa-2b/RBV signif-
icantly increased SVR (approximately 70%) in both arms over standard of care.
Compared to 44 weeks of triple therapy after the lead-in period, response-guided
therapy with lead-in plus 24 boceprevir plus PEG-IFN alfa-2b/RBV ± 20 PEG-IFN
alfa-2b/RBV produced comparable SVR [2]. Modiﬁed from N Engl J Med. 2011 Mar
31;364(13):1195–1206.Sprint-2
Sprint-2 consists of a phase 3 international double-blind random-
ized study including genotype 1 naïve patients (938 non-black
and 159 black) [2]. The design of the trial is presented in Fig. 1A.
SVR in non-black patients was 40% for SOC and signiﬁcantly
higher (p <0.0001) in both boceprevir arms: response-guided
therapy (67%) and lead-in phase followed by 44 weeks boceprevir
plus PEG-IFN alfa-2b/ribavirin (68%); corresponding SVR in black
patients were, respectively, 23%, 42% (p = 0.044) and 53%
(p = 0.004) (Fig. 1B). For non-black patients receivingP1 dose of
boceprevir or placebo, the respective SVR was 42%, 70%, and
71%. SVR rates were comparable for (i) 44 weeks of triple therapy
after the lead-in period, and (ii) response-guided therapy with
lead-in plus 24 boceprevir plus PEG-IFN alfa-2b/ribavirin ± 20
PEG-IFN alfa-2b/ribavirin. Anemia was reported in 29% of controls
vs. 49% in the boceprevir arms, leading to dose reduction in 13%
and 21% and discontinuation in 1% and 2%, respectively.
What have we learned from Sprint-2 study?
First, the high rate of response: boceprevir plus PEG-IFN alfa-2b/
ribavirin signiﬁcantly increased SVR (to approximately 70%) in
both arms over SOC. Approximately two-thirds of patients
achieved RVR and remained HCV RNA negative through 24 weeks
and thus beneﬁted from a reduction of treatment to 24–
28 weeks. Baseline predictors of non response were aged over
40 years, black in ethnicity, baseline HCV RNA levelJournal of Hepatology 2011>400,000 IU/ml, cirrhosis, and not receiving boceprevir. More-
over, a decrease in the HCV RNA level by 1 log10 IU/ml or more
at the end of the 4-week lead-in period was strongly predictive
of a SVR. In an expanded model that included response data dur-
ing the treatment period, an HCV RNA level at week 4 which was
undetectable or which had decreased by 1 log10 IU/ml or more
from baseline, had the highest odds ratio. RVR was already
described as a strong predictor of SVR [4].
Second, the strategy used in the lead-in phase. In one arm,
boceprevir was added after a lead-in period of treatment with
peginterferon–ribavirin alone. Theoretically, a lead-in phase
would serve to reduce HCV RNA levels before exposure to a pro-
tease inhibitor, thereby reducing the risk of viral breakthrough or
resistance to the direct-acting antiviral agent, as noted in a previ-
ous phase 2 study [5]. Patients with a poor response to interferon,
deﬁned as a reduction in the HCV RNA level of less than
1 log10 IU/ml after 4 weeks, might wait for a combination of mul-
tiple DAAs and avoid protease monotherapy, unless they have cir-
rhosis. Patients with an RVR have high SVR and they might not
require a protease inhibitor and may only require pegylated
interferon plus ribavirin.vol. 55 j 1154–1158 1155
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Fig. 2. Respond 2 study. (A) Design: in this trial, three arms were randomly
selected from 403 HCV genotype 1 patients who had previously failed treatment–
partial/non-responders or relapsers. At 24 weeks after end of treatment, the
control arm achieved a SVR of 21 percent. Adding Boceprevir to the treatment
increased SVR to 59 percent for the second arm and 67 percent for the third arm.
It was noted that previous relapsers had better SVR than nonresponders in all
International Hepatology
What about resistance?
During monotherapy, viral variants with substitutions at 6 main
positions within the NS3 protease (36, 54, 55, 155, 156, and 170)
were selected. Phenotypic analyses of resistance based on in vitro
replicons, showed different levels of resistance conferred by sub-
stitutions at these different positions. Changes at positions 36, 54,
55, 155, and 156 conferred moderate resistance [6]. Cross resis-
tance studies have shown that most of the known resistance
mutations confer resistance to most of the protease inhibitors
in development. Subtype 1a leads to more resistance than 1b;
therefore subtyping will be needed prior to treatment. HCV resis-
tance to boceprevir is signiﬁcantly less frequent when adminis-
tered in combination with PEG-IFN and ribavirin. The Sprint-1
phase II study showed that a standard dose of ribavirin is crucial
to improve SVR and prevent resistance. Even though the mecha-
nism of action of ribavirin is poorly understood, this drug appears
important in future combinations. Also, in the SOC, treating HCV
without ribavirin or prematurely discontinuing it, is associated
with a signiﬁcant decline in virological response, and an increase
in both breakthrough viraemia and relapse [7].
What about the safety proﬁle?
Dysgeusia and anemia were reported more commonly in the
boceprevir groups than in the control group. The regimens that
included boceprevir were associated with increased rates of ane-
mia, and nearly twice of boceprevir recipients compared to con-
trols had a hemoglobin level lower than 9.5 g/dl or received
erythropoietin (43% vs. 24%). Neither the incidence of serious
adverse events nor the frequency of discontinuation owing to
an adverse event differed signiﬁcantly between patients receiving
boceprevir and those receiving standard therapy.arms [3]. (B) Results. Combination therapy adding Boceprevir yields higher
sustained SVR rates for patients with HCV genotype 1 that did not respond to or
relapse after treatment with PEG-IFN and RBV were reported [3]. Modiﬁed from N
Engl J Med. 2011 Mar 31;364(13):1207–17.
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Fig. 3. Prediction of treatment response with rs12979860 polymorphism in
Sprint-2 study. There is no beneﬁt of triple therapy with boceprevir, in patients
with rs12979860 CC polymorphism. Improvement in SVR in naïve patients is
greater with T allele [12].Respond 2 study
The ﬁnal results of this trial demonstrated that combination ther-
apy with Boceprevir yields higher sustained SVR rates for patients
with HCV genotype 1 who did not respond to or relapsed after
treatment with PEG-IFN and ribavirin [3]. In this trial, three arms
were randomly selected from 403 HCV genotype 1 patients who
were previously failed treatment-partial/non-responders or
relapsers (Fig. 2A).
A total of 403 patients were treated. The rate of SVR was sig-
niﬁcantly higher in the two boceprevir groups (group 2, 59%;
group 3, 66%) than in the control group (21%, p <0.001)
(Fig. 3B). Among patients with an undetectable HCV RNA level
at week 8, the rate of SVR was 86% after 32 weeks of triple ther-
apy and 88% after 44 weeks of triple therapy. Among the 102
patients with a decrease in the HCV RNA level of less than
1 log10 IU/ml at treatment week 4, the rates of SVR were 0%,
33%, and 34% in groups 1, 2, and 3, respectively. Anemia was con-
siderably more common in the boceprevir-treated groups than in
the control group, and erythropoietin was administered in 41 to
46% of boceprevir-treated patients and 21% of controls.
What have we learned from Respond-2 study?
First, very important high rate of response in this difﬁcult-
to-treat patients: the rates of SVR among patients with prior1156 Journal of Hepatology 2011relapse were 29% in group 1, versus 69% and 75% in group 2
and group 3, respectively; among patients with prior non-
response, the corresponding rates were 7% versus 40% and 52%.
A total of 102 patients (15%, 28%, and 27% in groups 1, 2, and 3,
respectively) had a poor response to interferon, deﬁned as a
decrease in the HCV RNA level of less than 1 log10 IU/ml aftervol. 55 j 1154–1158
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the 4-week lead-in period. In this subgroup, a SVR was achieved
in none of the patients in group 1 and in 33% and 34% in groups 2
and 3, respectively. Among patients who had a good response to
interferon (a decrease in HCV RNA level of 1 log10 IU/ml or more
at treatment week 4), the rates of SVR were 25%, 73%, and 79% in
group 1, group 2 and group 3, respectively.
Early response (i.e., an undetectable HCV RNA level at week 8)
was associated with a high rate of SVR in all three groups (7 out
of 7 patients [100%] in group 1; 64 out of 74 patients [86%] in
group 2; and 74 out of 84 patients [88%] in group 3). The propor-
tion of patients with an undetectable HCV RNA level at week 8 in
the boceprevir groups (74 out of 162 patients [46%] in group 2
and 84 out of 161 patients [52%] in group 3) was approximately
six times the proportion of group 1 (7 out of 80 [9%]).
What about predictors of SVR?
Predictive factors associated with SVR were: receiving bocepre-
vir, previous relapse when compared to previous non-response,
low viral load at baseline, and absence of cirrhosis. When the
decline in viral load (i.e., decrease from baseline in the HCV
RNA level of P1 log10 IU/ml vs. <1 log10 IU/ml) at week 4 was
added to the model, the week 4 response was a stronger predictor
of SVR than historical response (OR, 5.2; p <0.001).
Which patients beneﬁt from a shorten treatment duration?
Patients with undetectable HCV RNA levels at treatment week 8
were shown to have a rate of sustained virological response that
was similar, whether boceprevir was taken for 32 weeks or
44 weeks. Thus an early response identiﬁed patients who could
beneﬁt from a shorter treatment.
What about resistance?
Assessment for amino acid variants associated with reduced sus-
ceptibility to boceprevir was performed for 114 patients in group
2 or group 3 in whom a sustained virological response did not
occur. Post-baseline data were available for 98 of the 114 patients
(86%), with variants detected in 43 of these 98 patients (44%). The
rate of amino acid variants associated with reduced susceptibility
to boceprevir was higher among patients with a poor response to
interferon (13 of 46 [28%] in group 2 and 15 of 44 [34%] in group
3) than among patients with a good response to interferon (10 of
110 [9%] in group 2 and 7 of 112 [6%] in group 3).
Interestingly, the authors identiﬁed 102 patients with a poor
response to interferon, deﬁned as a decrease in the HCV RNA level
of less than 1 log10 IU/ml at week 4. Notably, a SVR was achieved,
after boceprevir was added to the SOC, in 33% to 34% of the
patients with a poor response to interferon, as compared to 0%
in the patients retreated with SOC alone. It has been previously
reported that in non-responders, some interferon stimulated
genes were highly expressed; thus, pre-activation of the IFN sys-
tem in patients appears to limit the effect of IFN antiviral therapy
[8]. The failure to respond to exogenous PEG-IFN in non-respond-
ers could indicate a blunted response to IFN. However, the addi-
tion of a protease inhibitor might restore IFN responsiveness [8].
There was a higher incidence of anemia in the groups receiv-
ing boceprevir (43% to 46%) than in the control group (20%). Con-
sistent with the increased incidence of anemia, the proportion of
patients with hemoglobin levels from 6.5 to less than 9.5 g/dl wasJournal of Hepatology 2011higher in groups 2 and 3 than in group 1; however, discontinua-
tion owing to anemia was infrequent (occurring in 0% of patients
in group 1 and group 2 and in 3% [5 of 161 patients] in group 3).
Erythropoietin was administered to 21%, 41%, and 46% of patients
in groups 1, 2 and 3, respectively. Dysgeusia, rash, and dry skin
were reported more frequently in the boceprevir groups than in
the control group.
Regarding the genetic prediction of treatment response, very
consistent data were reported by independent groups studying
SNPs near the IL28B (IFN-c3) region and its association with
treatment response, thus opening a window for personalized
medicine [9–10]. Although all of the identiﬁed variants lie in or
near the IL28B gene, none of them has an obvious effect on the
function of this gene [11]. Interestingly, in the Sprint-2 study,
improvement in SVR in naïve genotype 1 patients was greater
with the rs12979860 T allele, and those with the rs12979860
CC genotype had no beneﬁt of the triple therapy over SOC [12].
However, we have to remember that genetic variants might show
strong association at the population level, but are imperfect pre-
dictors at the individual level. We need more information on
IL28B prediction power with triple therapy prior to proposing a
personalized treatment.
Finally, a major breakthrough has been achieved with triple
therapy when boceprevir is added to SOC. There has been a
Sprint-2 increase Respond-2 treatment. Also, in genotype 1 naïve
and experienced patients, promising results have been reported
when telaprevir, is added to the current SOC, PEG-IFN plus riba-
virin [13–14]. The very near future SOC for genotype 1 patients
will consist in the addition of boceprevir or telaprevir to PEG-
IFN plus ribavirin.
This led to major expectancies but also caution. There will be
major educational needs to achieve good clinical use of the
treatment.
First, knowledge of treatment response predictors will include
genotype 1 subtype, and also all previously known predictors
(RVR, etc.). The power of testing IL28B polymorphisms to predict
SVR for triple therapy is not completely evaluated currently and
cannot be recommended at this time. Naïve patients who
achieved RVR and extended therapy beneﬁt from a shorter dura-
tion treatment. The treatment has to be well explained and
simpliﬁed.
Second, it will be important to focus on compliance. In addi-
tion to PEG-IFN and ribavirin, boceprevir is administered orally
at a dose of 800 mg three times daily (to be taken with food at
an interval of 7–9 h between doses) in four capsules of 200 mg
each. Compliance will be an issue, since poor compliance is asso-
ciated with failure and resistance.
Third, management of side effects and treatment dose adapta-
tion will be important. Frequent physical examinations together
with laboratory testing for anemia to adapt dosing will be
needed. Last but not least, measurements of HCV RNA for moni-
toring drug resistance will be mandatory. HCV RNA assays based
on real-time PCR will have to be done frequently. A viral break-
through in a compliant patient is very likely to be drug resistance
and is a stopping rule.
In the future, we do hope that once several DDAs become
available, treatment strategies will include a combination of sev-
eral drugs with different mechanisms of action (protease inhibi-
tors plus polymerase inhibitors) that could hopefully result in
IFN- and/or ribavirin-sparing regimens leading to additive
potency, lacking cross resistance and with a good safety proﬁle.vol. 55 j 1154–1158 1157
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